Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
ln Vitro |
Alamandine is made either directly from angiotensin 1-7 (Ang-(1-7)) or via ACE2 catalyzing Ang A. It is produced from angiotensin II (Ang II) by the Ang II converting enzyme 2 (ACE2), and because of this, it has protective (vasodilatory) qualities. It is possible to decarboxylate Ang (1–7) to produce the peptide alamandine. Another endogenous peptide that can be found in human blood is alamandine [1]. In primary endothelial and mesangial cells, alamandine raises the concentration of cAMP, which also suggests Gs coupling [2]. Leptin secretion, expression, and blood levels are all reduced by amandine. In both isolated adipocytes and adipose tissue, alamandine stimulates the expression of plasminogen activator inhibitor-1 (PAI-1) and iNOS [2].
|
---|---|
ln Vivo |
After six weeks of treatment with alamandine (0.15 μL/h; given by mini-osmotic pump), hypertension was improved and left ventricular (LV) function was compromised in patients with SHR. Additionally, it slowed the growth of the cross-sectional area of myocardial cells, decreased the mass increase of the heart and lungs in SHR, and decreased the levels of brain and atrial natriuretic peptide mRNA[3].
|
Animal Protocol |
Animal/Disease Models: Male spontaneously hypertensive rats (SHRs, 50weeks old)[3]
Doses: 0.15 μL/h (~50 μg/kg/day) Route of Administration: Administered by mini-osmotic pumps; for 6 weeks Experimental Results: Attenuated hypertension , alleviated cardiac hypertrophy, and improved LV function. |
References |
[1]. Daniel C Villela, et al. Alamandine: a new member of the angiotensin family. Curr Opin Nephrol Hypertens. 2014 Mar;23(2):130-4.
[2]. Johanna Schleifenbaum. Alamandine and Its Receptor MrgD Pair Up to Join the Protective Arm of the Renin-Angiotensin System. Front Med (Lausanne). 2019 Jun 11;6:107. [3]. Chi Liu, et al. Alamandine attenuates hypertension and cardiac hypertrophy in hypertensive rats. Amino Acids. 2018 Aug;50(8):1071-1081. |
Molecular Formula |
C40H62N12O9
|
---|---|
Molecular Weight |
855.00
|
CAS # |
1176306-10-7
|
SMILES |
FC(C(=O)O)(F)F.O=C([C@H](CC1=CN=CN1)NC([C@H]([C@@H](C)CC)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](C(C)C)NC([C@H](CCC/N=C(\N)/N)NC([C@H](C)N)=O)=O)=O)=O)=O)N1CCC[C@H]1C(=O)O
|
Solubility (In Vitro) |
H2O: 25 mg/mL (29.24 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (29.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.1696 mL | 5.8480 mL | 11.6959 mL | |
5 mM | 0.2339 mL | 1.1696 mL | 2.3392 mL | |
10 mM | 0.1170 mL | 0.5848 mL | 1.1696 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.